Rohit Gosain, MD

Update from the POLARIX Study on Pola-R-CHP in DLBCL

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in leukemia and lymphoma.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

SWOG S1826: Nivolumab-AVD in Older Patients with Advanced Hodgkin Lymphoma

Medical oncologists discuss recent data from the POLARIX study investigating polatuzumab vedotin plus R-CHP in patients with diffuse large B-cell lymphoma.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

SEQUOIA: Biomarker Subgroup Analysis on Zanubrutinib in Treatment-Naïve CLL/SLL Without del(17p)

Mazyar Shadman, MD, MPH, and the Oncology Brothers discuss recent data from SWOG S1826 on nivolumab-AVD in patients aged 60 years and older with advanced stage Hodgkin lymphoma.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

ALPINE: Zanubrutinib in Relapsed/Refractory CLL and SLL

Experts on leukemia review the biomarker subgroup analysis from the SEQUOIA study looking at zanubrutinib in patients with treatment-naïve CLL/SLL without 17p deletion.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

Key Takeaways on Recent Data in Multiple Myeloma from ASH 2023

Following ASH 2023, Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the ALPINE study investigating zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Jens Hillengass, MD, PhD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD

KarMMA-3: Ide-Cel vs Standard Regimens in Triple-Class–Exposed RRMM

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD

Retrospective Study on Bortezomib Dosing in NDMM

Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD

IsKia: Isa-KRd vs KRd as Pre-Transplant Induction and Post-Transplant Consolidation in NDMM

Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD

PERSEUS: Dara-VRd vs VRd in Patients with NDMM Eligible for Autologous Stem Cell Transplantation

Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD

Key Takeaways on Recent Data in Breast Cancer from SABCS 2023

Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.

Rohit Gosain, MD; Rahul Gosain, MD; and Eleonora Teplinsky, MD, presenting slides

Rohit Gosain, MD;Rahul Gosain, MD;Eleonora Teplinsky, MD

December 16th 2023

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in breast cancer.

KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC

Rohit Gosain, MD;Rahul Gosain, MD;Eleonora Teplinsky, MD

ICARO: Nodal Burden and Recurrence in Patients With Isolated Tumor Cells

Medical oncologists discuss recent data from KEYNOTE-522 looking at event-free survival with neoadjuvant and adjuvant pembrolizumab in triple-negative breast cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Eleonora Teplinsky, MD

IDEA Trial: Endocrine Therapy Without Radiotherapy After Breast-Conserving Surgery

Eleonora Teplinsky, MD, and the Oncology Brothers discuss recent updates from the ICARO study following the 2023 San Antonio Breast Cancer Symposium.

Rohit Gosain, MD;Rahul Gosain, MD;Eleonora Teplinsky, MD

NSABP B-51: Loco-Regional Irradiation in Patients Who Become Node Negative After Neoadjuvant Chemotherapy

Experts on breast cancer review recent data updates from the IDEA trial investigating endocrine therapy without radiotherapy following breast-conserving surgery.

Rohit Gosain, MD;Rahul Gosain, MD;Eleonora Teplinsky, MD

Closing Thoughts on Recent Data in GI Cancers From ESMO 2023

Following SABCS 2023, Eleonora Teplinsky, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from NSABP B-51 on loco-regional irradiation in patients who became node negative after neoadjuvant chemotherapy.

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

GASTFOX: Evaluate FOLFOX With or Without Docetaxel (TFOX) as First-Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

CABINET: Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus

Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

Codebreak300: Sotorasib Plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer

Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.

Rohit Gosain, MD;Rahul Gosain, MD;Rachna Shroff, MD

Key Takeaways: Trial Data in NSCLC from ESMO 2023

Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.

Rohit Gosain, MD;Rahul Gosain, MD

LIBRETTO-431: 1L Selpercatinib in RET Fusion–Positive Advanced NSCLC

Following their program with expert Alexander Spira, MD, PhD, FACP, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, share key takeaways from ESMO 2023 centered on advancements in the management of NSCLC.

Rohit Gosain, MD;Rahul Gosain, MD

MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC

Alexander Spira, MD, PhD, FACP, joins the Oncology Brothers in reviewing data from LIBRETTO-431 and frontline selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Alexander Spira, MD, PhD

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: Results from MARIPOSA

Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.

Rohit Gosain, MD;Rahul Gosain, MD;Alexander Spira, MD, PhD

Updates from PAPILLON: 1L Amivantamab + Chemotherapy in Advanced NSCLC

Expert insight into results from MARIPOSA, a study of frontline amivantamab plus lazertinib in advanced non–small cell lung cancer, and the potential for this regimen’s use in real-world practice.

Rohit Gosain, MD;Rahul Gosain, MD;Alexander Spira, MD, PhD